Medline Inc. Class A Common Stock (MDLN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medline Inc. Class A Common Stock (MDLN) trades at $32.58 with AI Score 71/100 (Grade A). Medline Inc. is a manufacturer and distributor of medical supplies and solutions, serving various healthcare providers. Market cap: $27.6B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 7, 2026MDLN stock analysis for 2026: Analysts have set a consensus price target of $48.52 for Medline Inc. Class A Common Stock, suggesting 48.9% upside from the current price of $32.58. The AI MoonshotScore is 71/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MDLN: 2/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Medline Inc. Class A Common Stock (MDLN) Healthcare & Pipeline Overview
Medline Inc. is a global manufacturer and distributor of medical supplies, operating through Medline Brand and Supply Chain Solutions. The company provides a comprehensive portfolio of medical products and supply chain optimization services to hospitals, surgery centers, physician offices, and other healthcare facilities, competing with companies like ResMed Inc. and Avantor, Inc.
What Is the Investment Thesis for MDLN?
Medline Inc. presents a notable research candidate due to its established market position and comprehensive product offerings. With a market capitalization of $27.6B and a P/E ratio of 34.8, the company demonstrates financial stability. A key value driver is its integrated business model, encompassing both manufacturing and supply chain solutions, which allows for greater control over costs and service delivery. Growth catalysts include the expansion of its product lines and penetration into new geographic markets. However, potential risks include increasing competition in the medical supplies industry and fluctuations in raw material costs. The company's beta of 1.98 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
MDLN Key Highlights
Medline Inc. operates with a profit margin of 4.1%, reflecting its ability to generate earnings relative to revenue.
- The company's gross margin of 24.6% indicates the profitability of its products and services before operating expenses.
- Medline Inc. serves a diverse range of healthcare providers, including hospitals, surgery centers, physician offices, and nursing homes.
- The company's two segments, Medline Brand and Supply Chain Solutions, provide a comprehensive suite of products and services.
- Medline Inc. was founded in 1966 and has since grown into a major player in the medical supplies industry.
Who Are MDLN's Competitors?
MDLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RMD ResMed Inc. | $228.44 | -0.67% | $33.1B | 93 |
| COO The Cooper Companies, Inc. | $76.74 | +0.01% | $15.0B | 77 |
| AVTR Avantor, Inc. | $13.96 | +4.73% | $9.44B | 53 |
| BLCO Bausch + Lomb Corporation | $17.45 | +2.41% | $6.23B | 58 |
| NTSK Netskope, Inc. | $14.70 | -4.36% | $5.94B | — |
| MECNY Menicon Co Ltd | $88.63 | +0.00% | $26.9B | 55 |
| WST West Pharmaceutical Services, Inc. | $355.99 | +0.91% | $25.1B | 93 |
| ALC Alcon Inc. | $74.26 | +0.97% | $36.2B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDLN's Key Strengths?
Comprehensive product portfolio
- Integrated supply chain solutions
- Established customer relationships
- Strong market presence
What Are MDLN's Weaknesses?
Lower profit margin compared to some competitors
- Dependence on third-party suppliers for certain products
- Exposure to fluctuations in raw material costs
- High beta indicating higher volatility
What Could Drive MDLN Stock Higher?
Expansion of product lines in surgical solutions and front line care.
- Penetration into new geographic markets, particularly in emerging economies.
- Launch of innovative medical products addressing unmet clinical needs (within the next 1-2 years).
- Strategic acquisitions to expand product portfolio and market reach.
- Enhancement of supply chain solutions through technology and data analytics.
What Are the Key Risks for MDLN?
Rich valuation — a P/E of 34.8 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Insider selling — insiders were net sellers of roughly $3.4B recently.
- Increasing competition from established players and new entrants in the medical supplies industry.
- Regulatory changes impacting medical device approvals and reimbursement policies.
- Economic downturn affecting healthcare spending and demand for medical supplies.
- Fluctuations in raw material costs impacting profitability.
- Disruptions in the global supply chain affecting product availability and delivery.
What Are the Growth Opportunities for MDLN?
- Expansion of Surgical Solutions: Medline can capitalize on the growing demand for advanced surgical solutions by expanding its product portfolio and entering new surgical specialties. The global surgical instruments market is projected to reach $17.4 billion by 2027. By investing in research and development and strategic acquisitions, Medline can enhance its competitive position and capture a larger share of this market. This expansion can be realized within the next 2-3 years.
- Penetration into Emerging Markets: Medline has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is rapidly developing. These markets offer significant growth potential due to increasing healthcare expenditure and unmet medical needs. By establishing strategic partnerships and tailoring its product offerings to local market requirements, Medline can successfully penetrate these markets and drive revenue growth. This expansion can begin immediately and continue over the next 5 years.
- Enhancement of Supply Chain Solutions: Medline can further enhance its supply chain solutions by leveraging technology and data analytics to optimize inventory management, reduce costs, and improve service delivery. The global supply chain management market is projected to reach $27 billion by 2028. By investing in advanced supply chain technologies and expanding its service offerings, Medline can strengthen its competitive advantage and attract new customers. This enhancement can be implemented within the next 1-2 years.
- Development of Innovative Products: Medline can drive growth by developing innovative medical products that address unmet clinical needs and improve patient outcomes. By investing in research and development and collaborating with healthcare professionals, Medline can create differentiated products that command premium pricing and capture market share. The timeline for this growth opportunity depends on the specific product development cycles, but initial results can be expected within 3-5 years.
- Strategic Acquisitions: Medline can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. By carefully selecting acquisition targets and integrating them effectively, Medline can accelerate its growth and enhance its competitive position. The timeline for this growth opportunity is ongoing, as Medline continuously evaluates potential acquisition targets.
What Are MDLN's Competitive Advantages?
- Integrated Business Model: Medline's combination of manufacturing and supply chain solutions provides a competitive advantage.
- Extensive Product Portfolio: The company offers a wide range of medical products, catering to diverse customer needs.
- Established Customer Relationships: Medline has built long-term relationships with healthcare providers.
- Supply Chain Expertise: The company's supply chain optimization services enhance customer value and loyalty.
What Does MDLN Do?
Founded in 1966 and headquartered in Northfield, Illinois, Medline Inc. has grown into a major player in the medical supplies industry. The company operates through two primary segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment focuses on the procurement and manufacturing of medical products across three key categories: surgical solutions, front line care, and laboratory and diagnostics. Surgical solutions include surgical procedure trays, drapes, gowns, and surgical instruments. Front line care encompasses products for patient-facing needs such as wound care, gloves, and infection control. The laboratory and diagnostics category offers point of care testing, analyzers, and diagnostic consumables. The Supply Chain Solutions segment provides logistics and supply chain optimization services, including consulting, warehouse management, and inventory rationalization. Medline serves a diverse range of healthcare providers, including hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes, both domestically and internationally. Medline's integrated approach, from manufacturing to supply chain management, allows it to offer comprehensive solutions to its customers, differentiating it from competitors that may focus on specific product categories or services.
What Products and Services Does MDLN Offer?
- Manufactures and distributes medical supplies.
- Provides products to hospitals, surgery centers, and physician offices.
- Offers surgical solutions, including surgical trays and instruments.
- Supplies front line care products like wound care and gloves.
- Provides laboratory and diagnostic products, including analyzers and consumables.
- Offers supply chain optimization services to healthcare providers.
- Distributes third-party products from national brands.
How Does MDLN Make Money?
- Manufacturing and selling Medline-branded medical products.
- Distributing third-party medical products.
- Providing supply chain optimization services to healthcare providers.
- Generating revenue through product sales and service fees.
What Industry Does MDLN Operate In?
Medline Inc. operates in the medical instruments and supplies industry, a sector characterized by steady growth driven by an aging population, increasing healthcare expenditure, and technological advancements. The industry is competitive, with key players like ResMed Inc. and Avantor, Inc. vying for market share. Medline's integrated business model, encompassing both manufacturing and supply chain solutions, positions it favorably in this landscape. The global medical devices market is projected to reach $600 billion by 2026, indicating substantial growth opportunities for companies like Medline.
Who Are MDLN's Key Customers?
- Hospitals
- Surgery Centers
- Physician Offices
- Post-Acute Facilities
- Nursing Homes
Insider Activity
Over the past six months, Medline Inc. Class A Common Stock insiders filed 30 SEC Form 4 transactions — 26 sales and 4 purchases. On net that is roughly 129.5M shares disposed (about $3.4B), a signal worth weighing alongside the fundamentals.
MDLN Valuation & Market Position
With a $27.6B market cap, Medline Inc. Class A Common Stock sits in the large-cap segment of the market. Relative to its peer group, MDLN's quantitative score of 71/100 is roughly in line with the peer average of 70/100.
Key Financial Metrics
Return on equity for Medline Inc. Class A Common Stock stands at 6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. MDLN trades at a trailing price-to-earnings ratio of 34.82, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Medline Inc. Class A Common Stock's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.03 places it in the grey zone, a middle ground that warrants monitoring.
Forward Outlook
Wall Street analysts project Medline Inc. Class A Common Stock revenue of about $31.17B for fiscal 2026, with EPS near $1.53. The estimate reflects 15 contributing analysts.
Company Profile
Medline Inc. Class A Common Stock operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Northfield, US. The company is led by CEO James Boyle. MDLN has traded publicly since 2025.
MDLN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Community sentiment has turned increasingly positive, with discussions highlighting Medline's strong position in the healthcare supply chain.
- Analysts note that Medline's expansion into new markets could drive revenue growth, as demand for healthcare products continues to rise.
- The company's commitment to sustainability and innovation resonates well with socially-conscious investors, enhancing its brand appeal.
Bear Case
- Concerns about supply chain disruptions persist, which could hinder Medline's ability to meet growing demand and affect profitability.
- Recent bearish sentiment in online forums indicates a lack of confidence among some investors regarding the company's long-term strategy.
- Increased competition in the healthcare sector may pressure Medline's market share, as rivals innovate and lower prices.
- Economic uncertainties could impact healthcare spending, leading to cautious investor sentiment and potential revenue challenges for Medline.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MDLN Latest News
-
Tigress Financial Adjusts Medline Price Target to $55 From $62, Maintains Buy Rating
MT Newswires · Aug 14, 2026
-
Kaplan Fox Reminds Medline Inc. (MDLN) Investors of an Investigation into Potential Securities Law Violations
newsfilecorp.com · Aug 14, 2026
-
MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm
prnewswire.com · Aug 13, 2026
-
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
benzinga · Aug 13, 2026
MDLN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDLN.
Price Targets
Consensus target: $48.52
MDLN MoonshotScore
What does this score mean?
The MoonshotScore rates MDLN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Tigress Financial Adjusts Medline Price Target to $55 From $62, Maintains Buy Rating
Kaplan Fox Reminds Medline Inc. (MDLN) Investors of an Investigation into Potential Securities Law Violations
MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
Latest Medline Inc. Class A Common Stock Analysis
Leadership: James Boyle
CEO
James Boyle is the Chief Executive Officer of Medline Inc., leading a workforce of 43,000 employees. His career history includes extensive experience in the healthcare industry, with a focus on medical supplies and distribution. He has held various leadership positions within Medline, contributing to the company's growth and expansion. His educational background includes a degree in business administration and advanced training in supply chain management. Boyle's expertise lies in strategic planning, operational excellence, and customer relationship management.
Track Record: Under James Boyle's leadership, Medline Inc. has achieved significant milestones, including expanding its product portfolio, penetrating new geographic markets, and enhancing its supply chain capabilities. He has overseen strategic acquisitions that have strengthened the company's competitive position. Boyle has also focused on fostering a culture of innovation and customer centricity within the organization. His tenure has been marked by consistent revenue growth and improved operational efficiency.
What Investors Ask About Medline Inc. Class A Common Stock (MDLN) — Healthcare
What does the AI Score mean for MDLN?
MDLN holds an AI Score of 71/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation. Medline Inc. is a manufacturer and distributor of medical supplies and solutions, serving various healthcare providers. The company operates through its Medline Brand and Supply Chain Solutions …
What does Medline Inc. do?
Medline Inc. is a leading manufacturer and distributor of medical supplies and solutions, serving a wide range of healthcare providers, including hospitals, surgery centers, physician offices, and nursing homes. The company operates through two segments: Medline Brand, which focuses on manufacturing and procuring medical products, and Supply Chain Solutions, which provides logistics and supply chain optimization services.
What do analysts say about MDLN stock?
Analyst consensus on Medline Inc. suggests a positive outlook, driven by its strong market position and comprehensive product offerings. Key valuation metrics, such as its P/E ratio of 34.8 and gross margin of 24.6%, indicate financial stability and growth potential. Analysts also highlight the company's integrated business model and expansion into new markets as key growth drivers.
What are the main risks for MDLN?
The main risks for Medline Inc. include increasing competition in the medical supplies industry, which could put pressure on pricing and market share. Regulatory changes impacting medical device approvals and reimbursement policies could also pose a challenge. Economic downturns could affect healthcare spending and demand for medical supplies. Fluctuations in raw material costs could impact profitability.
What are the key growth opportunities for MDLN in healthcare?
Medline Inc. has several key growth opportunities within the healthcare sector. These include expanding its product offerings in high-growth areas such as surgical solutions and advanced wound care, increasing its presence in emerging markets with rapidly developing healthcare infrastructure, and leveraging technology to enhance its supply chain optimization services.
What revenue streams does Medline Inc. have in healthcare?
Medline Inc. generates revenue through several key streams within the healthcare sector. The primary revenue stream is the sale of Medline-branded medical products, including surgical solutions, front line care items, and laboratory and diagnostic equipment. Another significant revenue stream comes from the distribution of third-party medical products.
What are the key factors to evaluate for MDLN?
Medline Inc. Class A Common Stock (MDLN) holds an AI score of 71/100 (high). P/E: 34.8x vs the S&P 500's ~20-25x. Analysts target $48.52 (+49%). Not financial advice.
How frequently does MDLN data refresh on this page?
MDLN's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MDLN's recent stock price performance?
Medline Inc. Class A Common Stock (MDLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.
- Future performance is subject to market conditions and company-specific factors.